Fintel reports that on November 5, 2024, JP Morgan initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a Overweight ...

Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Century Therapeutics (IPSC – Research ...

Tuesday, Leerink Partners initiated coverage on shares of CAMP4 Therapeutics Corp (NASDAQ: CAMP) with an Outperform rating and a price target of $17.00. The coverage is based on the potential of ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

On Tuesday, Piper Sandler began coverage of CAMP4 Therapeutics Corp (NASDAQ:CAMP) stock with an Overweight rating and a price target of $18.00. The firm highlighted CAMP4's innovative work in the ...

Six months after launching with a mega-round of financing, Seaport Therapeutics has raised $225 million more to advance a lead drug candidate that could overcome some limitations of currently ...

Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings. Individual or entity Most recent transaction Date Shares owned as of transaction date 5AM PARTNERS VI, LLC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tuesday, Leerink Partners initiated coverage on shares of CAMP4 Therapeutics Corp (NASDAQ: CAMP) with an Outperform rating and a price target of $17.00. The coverage is based on the potential of the ...